Brief: Geron Updates NCCN Guidelines Recommending RYTELO for Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
26/07/2024 12:40
July 26 (Reuters) - Geron Corp GERN.O :
* GERON ANNOUNCES UPDATED NCCN GUIDELINES® RECOMMENDING
RYTELO™
(IMETELSTAT) FOR THE TREATMENT OF SYMPTOMATIC ANEMIA IN PATIENTS
WITH LOWER-RISK MDS
Source text for Eikon: ID:nBw8c8mPWa
Further company coverage: GERN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Geron
See all newsBrief: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Geron Corporation reports results for the quarter ended June 30 - Earnings Summary
Geron's Q2 revenue rises on RYTELO growth
Brief: Geron Q2 EPS USD -0.02
Brief: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)